AKT1 E17K mutant phosphorylates p21Cip1 and p27Kip1

Stable Identifier
R-HSA-2399969
Type
Reaction [transition]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
AKT1 E17K gain-of-function mutant preserves the ability to phosphorylate CDKN1B i.e. p27Kip1 (Malanga et al. 2008) and is expected to phosphorylate CDKN1A i.e. p21Cip1, like the wild-type AKT (Viglietto et al. 2002), although this has not been experimentally tested.
Literature References
PubMed ID Title Journal Year
18256540 Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung

Franco, R, De Rosa, N, Rocco, G, Savino, R, Malara, N, Malanga, D, Fabiani, F, Pirozzi, G, Scrima, M, De Marco, C, Tirino, V, De Gisi, S, Chiappetta, G, Viglietto, G

Cell Cycle 2008
12244303 Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer

Tsichlis, P, Viglietto, G, Santoro, M, Bruni, P, Vinci, F, Motti, ML, Califano, D, Fusco, A, Chiappetta, G, Melillo, RM, D'Alessio, A, Bellacosa, A

Nat Med 2002
Participants
Participates
Catalyst Activity

protein serine/threonine kinase activity of p-T308,S473-AKT1 E17K [cytosol]

Normal reaction
Functional status

Gain of function of p-T308,S473-AKT1 E17K [cytosol]

Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!